Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: LaurietCecília Monteiro, William Alvin McElveen, Seema Datta et al.|Neurology|2023Cited by 104
Peptide Level Immunoaffinity Enrichment Enhances Ubiquitination Site Identification on Individual ProteinsVeronica G. Anania, Donald S. Kirkpatrick|Molecular & Cellular Proteomics|2013Cited by 28